I-MAB (IMAB) said Friday that it has priced an underwritten offering of 33.3 million American depositary shares, representing 76.7 million ordinary shares, at $1.95 each for total proceeds of $65 million.
I-Mab said that it expects to close the offering around Tuesday, with the proceeds going toward clinical development of drug candidates and general corporate purposes.
Shares of I-Mab were up more than 18% in recent Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.